Novartis AG (NVS)

92.07
0.43 0.47
NYSE : Health Technology
Prev Close 91.64
Open 92.31
Day Low/High 92.01 / 92.46
52 Wk Low/High 74.97 / 96.31
Volume 926.53K
Avg Volume 1.69M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 231.29B
EPS 5.50
P/E Ratio 30.24
Div & Yield 1.84 (2.01%)

Latest News

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

We're seeing lots of companies snapping up their peers, and the market is applauding.

Novartis Is Moving Higher on the Charts, Go Long or Add to Longs

Novartis Is Moving Higher on the Charts, Go Long or Add to Longs

Let's check in on this Swiss-based pharmaceutical giant.

Medicines Co. and Novartis

Jim Cramer: Here's the Good News About the U.S./China Trade Delay

Jim Cramer: Here's the Good News About the U.S./China Trade Delay

There are plenty of stocks that have been thrown away for several weeks because of a belief that the Fed and a trade deal will avoid a recession.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Jim Cramer: Here's How to Look at Stocks in Earnings Season

Jim Cramer: Here's How to Look at Stocks in Earnings Season

On the biggest day for earnings reports in the S&P let me give you my scorecard to date so you know which pile your stocks might land in.

Big Biotech Receives Some Needed Shots in the Arm

Big Biotech Receives Some Needed Shots in the Arm

Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.

For Wealth and Safety Invest With a 'Shark'

For Wealth and Safety Invest With a 'Shark'

Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.

Charts of Alcon Look Good

Charts of Alcon Look Good

Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.

It's Tough to Weed Through the Data on Tilray

It's Tough to Weed Through the Data on Tilray

The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.

Should You Go for the 'Easy Money' in Novartis?

Should You Go for the 'Easy Money' in Novartis?

NVS been in an uptrend the past twelve months.

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.

Market Yin and Yang

We've got some push-pull in pre-market trading as moves lower in Netflix , Limelight Networks , United Rentals , SAP and Alcoa duel with Apple , which is moving higher pre-market, and positive moves in Novartis , eBay , Phillip Morris International ...

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point

Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point

Let's review the charts and indicators this morning.

Jim Cramer: The Forbidden City of Stock Sectors

Jim Cramer: The Forbidden City of Stock Sectors

Now, we know that if we got any sort of truce in the trade war, with the exception of the financials, these hated sectors would be loved.

Fibocall: Thursday Technical Texts

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.

Stock of the Day - Tilray

Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Medicine is a slow business and I view Gilead Sciences as a hold for now.

Excuse Me, Would You Like Some Cannabis With Your Coffee?

Excuse Me, Would You Like Some Cannabis With Your Coffee?

CBD could make coffee an around the clock craze.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.